Renal Failure Chronic Requiring Hemodialysis Clinical Trial
Official title:
Effects of Pharmacist on Medication-related Problems in Hemodialysis Patients: a Randomized,Controlled, Double-blind Study
The investigators propose that pharmacist interventions would reduce the amount of
unresolved medication-related problems in hemodialysis patients.
Condition:Hemodialysis patients
Intervention:Behavioral,Pharmacist intervention
Study Design:Randomized Allocation
Control: Active Control
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Introduction:
End stage renal disease (ESRD) incidence in Taiwan ranked first and prevalence ranked second
in the world from 2002 to 2005. Several foreign researches had reported that hemodialysis
(HD) patients often require 12 medications to treat 5 to 6 comorbid conditions. Besides,
ESRD is a lifelong disease and rates of compliance may diminish overtime. Thus, HD patients
may be at particular risk for drug related problems, durg-drug interactions and
noncompliance. Our aim is to analysis the effect of pharmacist in medication-related
problems in ambulatory hemodialysis patients.
Methods:
This study is a randomized double-blind, active controlled trial. The investigators will
invite and communicate with HD patients to find medication -related problems. After
pharmacist evaluation, pharmacist will do pharmaceutical interventions to resolve
medication-related problems, drug-drug interactions etc. in experimental group. In the
active control group, pharmacist in this study will not do pharmaceutical interventions. The
investigators will monitor each patient in a two-week period for medication-related
problems.
Our primary outcome is the amount of unresolved medication-related problems in each group
after two weeks. Blind outcome assessor will evaluate the amount of unresolved
medication-related problems in each case as well as compliance in these patients after two
weeks.
The investigators suppose that clinical pharmaceutical intervention will reduce the amount
of unresolved medication-related problem in experimental group. On the other hand, patients
without clinical pharmaceutical intervention will have more unresolved medication-related
problems.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01947673 -
Mechanisms of Intradialytic Hypertension
|
N/A | |
Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
Terminated |
NCT01982864 -
Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.
|
Phase 4 | |
Completed |
NCT01448174 -
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT01421771 -
Blood Pressure in Dialysis Patients
|
N/A | |
Completed |
NCT01722695 -
Performance Comparison of Revaclear With Larger Dialyzer
|
N/A | |
Withdrawn |
NCT01015313 -
Effects of Intensified Sodium Management in Hemodialysis Patients
|
N/A | |
Completed |
NCT02259413 -
Effect of an Exercise Rehabilitation Program on Symptoms in Hemodialysis
|
N/A | |
Not yet recruiting |
NCT02452788 -
Pharmaceutical Care in Ambulatory Hemodialysis Patients
|
N/A | |
Completed |
NCT01181544 -
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
|
N/A | |
Completed |
NCT01320202 -
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
|
Phase 3 | |
Completed |
NCT02285075 -
Temocillin Pharmacokinetic in Hemodialysis
|
Phase 4 | |
Completed |
NCT02825589 -
BIA-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients
|
N/A | |
Completed |
NCT00890045 -
Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
|
N/A | |
Not yet recruiting |
NCT02264964 -
Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis
|
N/A | |
Terminated |
NCT01312441 -
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
|
Phase 4 | |
Completed |
NCT01214928 -
Hemodialysis Vitamin D Pilot
|
N/A | |
Completed |
NCT00967993 -
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
|
Phase 2 | |
Completed |
NCT01981603 -
Transplant Navigator Dissemination
|
N/A | |
Completed |
NCT01578421 -
Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser
|
N/A |